SU 5402 | Tyrosine Kinase Inhibitor | AmBeed-信号通路专用抑制剂

SU 5402 {[allProObj[0].p_purity_real_show]}

货号：A781751

SU 5402 是一种有效的多靶点受体酪氨酸激酶抑制剂，靶向 VEGFR2、FGFR1 和 PDGFRβ，其 IC50 值分别为 20 nM、30 nM 和 510 nM。

SU 5402 化学结构
CAS号：215543-92-3

SU 5402 3D分子结构
CAS号：215543-92-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

EGFR 亚型比较

PDGFR 亚型比较

VEGFR 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM						99%+
Daphnetin	+ EGFR, IC50: 7.67 μM					PKA,PKC	95%
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		98%
PD168393	++++ EGFR, IC50: 0.70 nM						99%+
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		98%
Norcantharidin	✔						98%
CL-387785	++++ EGFR, IC50: 370 pM						98%
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	98%
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	98%
AG 555	+ EGFR, IC50: 0.7 μM						98%
AG 494	+ EGFR, IC50: 1.2 μM						99%+
AG-556	+ EGFR, IC50: 5 μM						98%
RG13022	+ EGFR, IC50: 4 μM						99%+
Tyrphostin RG 14620	✔						99%+
Vandetanib	+ EGFR, IC50: 500 nM						99%
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		99%
AZD3759	++++ EGFR (WT), IC50: 0.3 nM EGFR (L858R), IC50: 0.2 nM						98%
Erlotinib	++++ EGFR, IC50: 2 nM						95%
Saracatinib	+++ EGFR, IC50: 5 nM EGFR (L861Q), IC50: 4 nM						99%+
AG1557	✔						99%
Rociletinib	++ EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM						98%
AG490	+ EGFR, IC50: 0.1 μM						98%
Cetuximab	++++ EGFR, Kd: 0.39 nM						95%
Osimertinib	++ L858R/T790M EGFR, IC50: 11.44 nM WT EGFR, IC50: 12.92 nM						98%
Osimertinib mesylate	✔						98% (Content MsOH 15.2-18.2%)
Chrysophanol	✔					mTOR	98%
PD153035	++++ EGFR, Ki: 5.2 pM						99%+
Olmutinib	✔					BTK	99%+
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						99%+
Icotinib	+++ EGFR, IC50: 5 nM						99%
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						98%
Cyasterone	✔						99%+
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						98%
WZ8040	✔						99%+
(-)-Epigallocatechin Gallate	✔						99%
AG 18	+ EGFR, IC50: 35 μM						99%+
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						99%
Falnidamol	✔						99%+
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	99%+
Butein	✔						95%
Genistein	✔						98%
SU5214	+ EGFR, IC50: 36.7 μM						99%+
Naquotinib	✔						99%+
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		98%
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		99%
Lazertinib	++++ L858R/T790M EGFR, IC50: 2 nM WT EGFR, IC50: 76 nM				++++ Del19/T790M, IC50: 1.7 nM		99%+
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						99%+
MTX-211	✔					PI3K	98%
(E)-AG 99	✔						99%+
Licochalcone D	✔					Caspase,PARP	99%
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		97%
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		99%+
Firmonertinib mesylate	✔						99%+
Tyrphostin AG30	✔						99%+
EGFR-IN-12	++ EGFR, IC50: 21 nM						99%+
Mobocertinib	✔						98%
(Rac)-JBJ-04-125-02	✔						95%
(S)-Sunvozertinib	✔						99%
BLU-945	✔						95%
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			98%
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			99%+
ARRY-380 analog				✔			99%
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			99%+
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			98%
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			99%+
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			95%
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			98%
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms/CSF1R	98+%
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^T790M, IC50: 0.79 nM EGFR^L858R/T790M, IC50: 0.51 nM		98+%
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	98%
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			98%
Tucatinib				+++ ErbB2, IC50: 8 nM			98%
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Src,Raf	99%+
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			99%+
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	99%+
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			99%+
Afatinib dimaleate	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R/T790M), IC50: 0.4 nM			++ HER2, IC50: 14 nM			98%
Canertinib 2HCl	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			99%
Allitinib tosylate	++++ EGFR, IC50: 0.5 nM EGFR (T790M/L858R), IC50: 12 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			97%
Afatinib	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			99%
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			98%
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			99%
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			99%
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	99%
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	FLT3,ALK	98%
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	99%+
EAI045					✔		97%
Almonertinib					✔		99%
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		99%+
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				97%
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			VEGFR,mTOR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	99%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		98%+
Lactate			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	99%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2/Flk1, IC50: 3 nM VEGFR2, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	c-Kit,PDGFR,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/Flk1, IC50: 270 nM VEGFR2/KDR, IC50: 37 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms/CSF1R	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/Flk1, IC50: 0.18 nM VEGFR2/KDR, IC50: 0.2 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2/Flk1, IC50: 90 nM VEGFR2, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	FLT3,RET	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

SU 5402 生物活性

靶点

VEGFR2

VEGFR2, IC50:20 nM
FGFR1

FGFR1, IC50:30 nM

描述

SU5402 is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor.

SU 5402 细胞实验

Cell Line Human periodontal ligament cells Primary dental pulp cells Primate astrocytes Mouse spermatogonial stem cells (mSPG) Bladder tumour cell lines Human pluripotent stem cells (hPSCs) Human pluripotent stem cells Mouse embryonic fibroblasts (MEFs) MDCK cells BHK cells	Concentration	Treated Time	Description	References
Human periodontal ligament cells	10 µM	24-48 hours	To evaluate the effect of SU5402 on reversing FGF-2-mediated inhibition of SDF-1 α expression, results showed that SU5402 could inhibit the FGF-2-reduced expression of SDF-1 α	Int J Mol Med. 2012 Apr;29(4):569-73.
Primary dental pulp cells	5, 10, 20 µM	3 to 7 days	Inhibited FGFR signaling pathway, reducing FGF2-mediated increases in Dmp1 and Dspp expression	J Dent Res. 2015 Nov;94(11):1582-90.
Primate astrocytes	25 µM	48 hours	To assess the effect of SU5402 on primate astrocyte migration and proliferation, results showed that SU5402 completely inhibited astrocyte migration and proliferation.	J Neurosci. 2012 May 30;32(22):7477-92.
Mouse spermatogonial stem cells (mSPG)	10 µM	5 days	Blocking sFGF2 signaling significantly reduced the in vitro propagation of high-density cultured mSPG, leading to decreased mitosis and increased apoptosis	Cell Res. 2012 Apr;22(4):773-6.
Bladder tumour cell lines	0–50 µM	5 days	To evaluate the effect of SU5402 on the proliferation and viability of bladder tumour cells, results showed that SU5402 inhibited the proliferation and viability of FGFR3 mutant and wild-type cell lines at micromolar concentrations.	Br J Cancer. 2011 Jan 4;104(1):75-82.
Human pluripotent stem cells (hPSCs)	10 µM	8 days	SU5402, in combination with CHIR99021 and DAPT, accelerates the differentiation of hPSCs into neurons and induces TUBB3 expression by day 10.	Nat Biotechnol. 2012 Jul 1;30(7):715-20.
Human pluripotent stem cells	10 µM	8 days	SU5402, in combination with Activin A, further decreased the expression of the early eye field/neural retina marker Rax, indicating its role in directing cells toward the retinal pigment epithelium (RPE) fate during the optic vesicle to optic cup stages of eye development.	Stem Cells Transl Med. 2013 May;2(5):384-93.
Mouse embryonic fibroblasts (MEFs)	10 µM		MSPG did not expand in the 5F-MCM-SU5402 medium, indicating that the IVP-promoting effect of sFGF2 was mediated by receptors both on mSPG and on MEFs under normal culture conditions	Cell Res. 2012 Apr;22(4):773-6.
MDCK cells	10 µM	48 hours	Assessment of /H9004F508-CFTR chloride channel activity by short-circuit current analysis in Ussing chambers	Mol Cell Proteomics. 2012 Sep;11(9):745-57.
BHK cells	10 µM	48 hours	Validation of /H9004F508-CFTR cell surface expression by flow cytometry	Mol Cell Proteomics. 2012 Sep;11(9):745-57.

Cell Line

Concentration

Treated Time

Description

References

Human periodontal ligament cells

10 µM

24-48 hours

To evaluate the effect of SU5402 on reversing FGF-2-mediated inhibition of SDF-1 α expression, results showed that SU5402 could inhibit the FGF-2-reduced expression of SDF-1 α

Int J Mol Med. 2012 Apr;29(4):569-73.

Primary dental pulp cells

5, 10, 20 µM

3 to 7 days

Inhibited FGFR signaling pathway, reducing FGF2-mediated increases in Dmp1 and Dspp expression

J Dent Res. 2015 Nov;94(11):1582-90.

Primate astrocytes

25 µM

48 hours

To assess the effect of SU5402 on primate astrocyte migration and proliferation, results showed that SU5402 completely inhibited astrocyte migration and proliferation.

J Neurosci. 2012 May 30;32(22):7477-92.

Mouse spermatogonial stem cells (mSPG)

10 µM

5 days

Blocking sFGF2 signaling significantly reduced the in vitro propagation of high-density cultured mSPG, leading to decreased mitosis and increased apoptosis

Cell Res. 2012 Apr;22(4):773-6.

Bladder tumour cell lines

0–50 µM

5 days

To evaluate the effect of SU5402 on the proliferation and viability of bladder tumour cells, results showed that SU5402 inhibited the proliferation and viability of FGFR3 mutant and wild-type cell lines at micromolar concentrations.

Br J Cancer. 2011 Jan 4;104(1):75-82.

Human pluripotent stem cells (hPSCs)

10 µM

8 days

SU5402, in combination with CHIR99021 and DAPT, accelerates the differentiation of hPSCs into neurons and induces TUBB3 expression by day 10.

Nat Biotechnol. 2012 Jul 1;30(7):715-20.

Human pluripotent stem cells

10 µM

8 days

SU5402, in combination with Activin A, further decreased the expression of the early eye field/neural retina marker Rax, indicating its role in directing cells toward the retinal pigment epithelium (RPE) fate during the optic vesicle to optic cup stages of eye development.

Stem Cells Transl Med. 2013 May;2(5):384-93.

Mouse embryonic fibroblasts (MEFs)

10 µM

MSPG did not expand in the 5F-MCM-SU5402 medium, indicating that the IVP-promoting effect of sFGF2 was mediated by receptors both on mSPG and on MEFs under normal culture conditions

Cell Res. 2012 Apr;22(4):773-6.

MDCK cells

10 µM

48 hours

Assessment of /H9004F508-CFTR chloride channel activity by short-circuit current analysis in Ussing chambers

Mol Cell Proteomics. 2012 Sep;11(9):745-57.

BHK cells

10 µM

48 hours

Validation of /H9004F508-CFTR cell surface expression by flow cytometry

Mol Cell Proteomics. 2012 Sep;11(9):745-57.

SU 5402 动物实验

Species Chicken C57BL/6 mice Zebrafish Mice	Animal Model NMDA-induced retinal damage model Chronic Unpredictable Stress Model Spinal cord injury model Sumf1/ mice	Administration	Dosage	Frequency	Description	References
Chicken	NMDA-induced retinal damage model	Intravitreal injection	0.8 μg/dose	Injected 6 hours and 24 hours after NMDA treatment, lasting for 3 days	Inhibit FGF receptor, reduce proliferation of Müller glia	Glia. 2009 Jan 15;57(2):166-81
C57BL/6 mice	Chronic Unpredictable Stress Model	Intracerebroventricular injection	2.5 μg/day	Once daily for 9 days	SU5402 blocked the antidepressant behavioral effects of fluoxetine in the CUS model and blocked fluoxetine-induced cell proliferation in the PFC	Biol Psychiatry. 2012 Aug 15;72(4):258-65
Zebrafish	Spinal cord injury model	Injection at the lesion site	5 µg/µl	Single injection, observed up to 3 weeks	To assess the effect of SU5402 on glial cell proliferation, migration, and axonal regeneration post-spinal cord injury in zebrafish, results showed that SU5402 inhibited glial cell proliferation and migration and prevented axonal regeneration.	J Neurosci. 2012 May 30;32(22):7477-92.
Mice	Sumf1/ mice	Intraperitoneal injection	500 µM	Single injection, analyzed at P21–P27	By inhibiting FGF1 signaling in vivo with SU5402, the terminal differentiation of Sumf1/ mice was unlocked. The results showed that SU5402 significantly increased the frequency of intermediate precursors and terminally differentiated CD71Ter119+ cells in the BM, indicating the rescue of the block of erythroid lineage differentiation	J Exp Med. 2010 Aug 2;207(8):1647-60

Species

Chicken C57BL/6 mice Zebrafish Mice

Animal Model

NMDA-induced retinal damage model Chronic Unpredictable Stress Model Spinal cord injury model Sumf1/ mice

Administration

Dosage

Frequency

Description

References

Chicken

NMDA-induced retinal damage model

Intravitreal injection

0.8 μg/dose

Injected 6 hours and 24 hours after NMDA treatment, lasting for 3 days

Inhibit FGF receptor, reduce proliferation of Müller glia

Glia. 2009 Jan 15;57(2):166-81

C57BL/6 mice

Chronic Unpredictable Stress Model

Intracerebroventricular injection

2.5 μg/day

Once daily for 9 days

SU5402 blocked the antidepressant behavioral effects of fluoxetine in the CUS model and blocked fluoxetine-induced cell proliferation in the PFC

Biol Psychiatry. 2012 Aug 15;72(4):258-65

Zebrafish

Spinal cord injury model

Injection at the lesion site

5 µg/µl

Single injection, observed up to 3 weeks

To assess the effect of SU5402 on glial cell proliferation, migration, and axonal regeneration post-spinal cord injury in zebrafish, results showed that SU5402 inhibited glial cell proliferation and migration and prevented axonal regeneration.

J Neurosci. 2012 May 30;32(22):7477-92.

Mice

Sumf1/ mice

Intraperitoneal injection

500 µM

Single injection, analyzed at P21–P27

By inhibiting FGF1 signaling in vivo with SU5402, the terminal differentiation of Sumf1/ mice was unlocked. The results showed that SU5402 significantly increased the frequency of intermediate precursors and terminally differentiated CD71Ter119+ cells in the BM, indicating the rescue of the block of erythroid lineage differentiation

J Exp Med. 2010 Aug 2;207(8):1647-60

SU 5402 参考文献

SU 5402 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.37mL

0.67mL

0.34mL

16.87mL

3.37mL

1.69mL

33.75mL

6.75mL

3.37mL

SU 5402 技术信息

CAS号	215543-92-3
分子式	C₁₇H₁₆N₂O₃
分子量	296.32
SMILES Code	O=C(O)CCC1=C(/C=C2C(NC3=C\2C=CC=C3)=O)NC=C1C
MDL No.	MFCD08235144

别名
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 30 mg/mL(101.24 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

mouse HER14 cells	Function assay	Inhibition of EGFR in mouse HER14 cells assessed as inhibition of EGF-stimulated Shc phosphorylation by immunoblotting	9139660
mouse NIH/3T3 cell	Function assay	Inhibition of acidic FGF-stimulated FGFR1 tyrosine autophosphorylation in mouse NIH/3T3 cells by immunoblottingm, IC50=10 μM	9139660
mouse NIHIR cells	Function assay	Inhibition of insulin-stimulated insulin receptor beta subunit autophosphorylation in mouse NIHIR cells	9139660

SU 5402 {[allProObj[0].p_purity_real_show]}

SU 5402 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

SU 5402 质控信息

SU 5402 生物活性

SU 5402 细胞实验

SU 5402 动物实验

SU 5402 参考文献

SU 5402 实验方案

SU 5402 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

靶点	VEGFR2 VEGFR2, IC50:20 nM FGFR1 FGFR1, IC50:30 nM
描述	SU5402 is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor.

SU 5402 {[allProObj[0].p_purity_real_show]}

SU 5402 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

SU 5402 质控信息

SU 5402 生物活性

SU 5402 细胞实验

SU 5402 动物实验

SU 5402 参考文献

SU 5402 实验方案

SU 5402 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

SU 5402 纯度/质量文件产品仅供科研